CD8A and neoplasm: In the study by Justin involving a mouse tumor model, the results indicated that the dose-differentiated radiotherapy promoted the clonal expansion of effector CD8 T cells, and when combined with ICIs, heterogeneous radiotherapy yielded stronger antitumor immune responses than homogeneous radiotherapy (16).